An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by ATEED

Date: Friday, 22nd July, 2016
Time: 4:30pm Networking, Presentation 5pm followed by drinks and nibbles.
Venue: SBS Reception Lounge (Common Room), School of Biological Sciences.
Guest Speaker:  This month we welcome Doug Wilson speaking on Adherium: a 14 year story of resilience and rapid change

The story of Adherium is a 14 year story of resilience and rapid change. Digital medicine requires the development of software, firmware, telecommunications, the marriage of sensors and astute positioning of monitoring devices, and a clear view of how this might these assist the target patients. The company began as Nexus6 in 2001 created by its current CEO, Garth Sutherland who, as an asthma sufferer, knew that patients with chronic respiratory disease exacerbated their condition by suboptimal use of their medication. The Smartinhaler was born: a digital device that monitors inhaler usage and encourages patients to maintain medication at the right levels for their condition. Clinical trials have shown outstanding improvements. Tens of thousands of patients on over 30 countries are currently being monitored daily. Data is king.

A restructure in 2015 saw the company become Adherium, partner AstraZeneca, the world leader in inhalers, list on the ASX, obtain regulatory approvals in new markets and extend their partnering to additional pharmaceutical companies. In his talk Doug Wilson will discuss the journey from a New Zealand start-up to a respected global corporation.

Garth Sutherland and his Adherium team have shown that serious, innovative creativity is alive and well in NZ, but commercial success demands this has to be coupled with huge persistence and imagination, a fierce approach to solving problems, and a passion for beating your international competition. Matching the local guys might give a nice buzz, but the target is the world.

Doug Wilson has had a remarkable international career becoming head of the Boehringer Ingelheim worldwide medical research group overseeing all research programmes and working on upward of 100 drugs and then as their head of Medicine and Regulatory Affairs.

Prior to that he worked for the company for ten years in the USA where he oversaw a team of 400; including a number of medical staff and was responsible for over 50 parallel drug developments.

Today he is Chair of Adherium, Director of ASX-listed biotech Phylogica (a drug discovery company) and is a director of AFT Pharmaceuticals.

Please reply YES in the subject line by email

Date and time
4.30-6.30 pm drinks and canapés (for 5.00 pm presentation), 22nd July

Reception Lounge, at the IIB and SBS entrance to the Thomas Building, 3a Symonds St (see map).

University is well serviced by bus routes, and car parking is available under the University of Auckland Business School (the Owen G Glenn Building) on Grafton Rd.